C3 Glomerulopathy

Pediatric Nephrology

Volumn 32, Issue 1, 2017, Pages 43-57

  Riedl, Magdalena ^a,b   Thorner, Paul ^c,d   Licht, Christoph ^a,c,e  

^a HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

C3 Glomerulopathy; C3 Nephritic factor; Complement; Dense deposit disease; Eculizumab; Membranoproliferative glomerulonephritis

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CALCINEURIN INHIBITOR; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C3; COMPLEMENT FACTOR H; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MYCOPHENOLATE MOFETIL; RITUXIMAB; C3 PROTEIN, HUMAN; NEPHRITIC FACTOR;

ARTICLE; C3 GLOMERULOPATHY; CLINICAL FEATURE; COMPLEMENT ALTERNATIVE PATHWAY; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; ELECTRON MICROSCOPY; END STAGE RENAL DISEASE; GLOMERULOPATHY; HISTOPATHOLOGY; HUMAN; IMMUNE COMPLEX NEPHRITIS; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; ANIMAL; DISEASE MODEL; PATHOLOGY;

ANIMALS; COMPLEMENT C3; COMPLEMENT C3 NEPHRITIC FACTOR; DISEASE MODELS, ANIMAL; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; HUMANS; TREATMENT OUTCOME;

EID: 84964000443     PISSN: 0931041X     EISSN: 1432198X     Source Type: Journal    
DOI: 10.1007/s00467-015-3310-4     Document Type: Article

References (120)

1. Sethi S, Fervenza FC (2012) Membranoproliferative glomerulonephritis—a new look at an old entity. N Engl J Med 366:1119–1131
2. Sethi S, Fervenza FC (2011) Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification. Semin Nephrol 31:341–348
3. Pickering MC, D'Agati VD, Nester CM, Smith RJ, Haas M, Appel GB, Alpers CE, Bajema IM, Bedrosian C, Braun M, Doyle M, Fakhouri F, Fervenza FC, Fogo AB, Fremeaux-Bacchi V, Gale DP, Goicoechea De Jorge E, Griffin G, Harris CL, Holers VM, Johnson S, Lavin PJ, Medjeral-Thomas N, Paul Morgan B, Nast CC, Noel LH, Peters DK, Rodriguez De Cordoba S, Servais A, Sethi S, Song WC, Tamburini P, Thurman JM, Zavros M, Cook HT (2013) C3 glomerulopathy: consensus report. Kidney Int 84:1079–1089
4. Zand L, Fervenza FC, Nasr SH, Sethi S (2014) Membranoproliferative glomerulonephritis associated with autoimmune diseases. J Nephrol 27:165–171
5. Zand L, Kattah A, Fervenza FC, Smith RJH, Nasr SH, Zhang Y, Vrana JA, Leung N, Cornell LD, Sethi S (2013) C3 glomerulonephritis associated with monoclonal gammopathy: a case series. Am J Kidney Dis 62:506–514
6. Rennke HG (1995) Secondary membranoproliferative glomerulonephritis. Kidney Int 47:643–656
7. Sethi S, Gamez JD, Vrana JA, Theis JD, Bergen HR 3rd, Zipfel PF, Dogan A, Smith RJH (2009) Glomeruli of dense deposit disease contain components of the alternative and terminal complement pathway. Kidney Int 75:952–960
8. Sethi S, Vrana JA, Theis JD, Dogan A (2013) Mass spectrometry based proteomics in the diagnosis of kidney disease. Curr Opin Nephrol Hypertens 22:273–280
9. Fervenza FC, Smith RJH, Sethi S (2012) Association of a novel complement factor H mutation with severe crescentic and necrotizing glomerulonephritis. Am J Kidney Dis 60:126–132
10. Cook HT, Pickering MC (2015) Histopathology of MPGN and C3 glomerulopathies. Nat Rev Nephrol 11:14–22
11. Walker PD (2007) Dense deposit disease: new insights. Curr Opin Nephrol Hypertens 16:204–212
12. Sethi S, Fervenza FC, Zhang Y, Zand L, Meyer NC, Borsa N, Nasr SH, Smith RJH (2013) Atypical postinfectious glomerulonephritis is associated with abnormalities in the alternative pathway of complement. Kidney Int 83:293–299
13. Hou J, Markowitz GS, Bomback AS, Appel GB, Herlitz LC, Barry Stokes M, D'Agati VD (2014) Toward a working definition of C3 glomerulopathy by immunofluorescence. Kidney Int 85:450–456
14. Sethi S, Nasr SH, De Vriese AS, Fervenza FC (2015) C4d as a diagnostic tool in proliferative GN. J Am Soc Nephrol 26:2852–2859
15. Bonsdorff M, Ponka A, Tornroth T (1984) Mycoplasmal pneumonia associated with mesangiocapillary glomerulonephritis type II (dense deposit disease). Acta Med Scand 216:427–429
16. Nasr SH, Valeri AM, Appel GB, Sherwinter J, Stokes MB, Said SM, Markowitz GS, D'Agati VD (2009) Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients. Clin J Am Soc Nephrol 4:22–32
17. Al-Ghaithi B, Chanchlani R, Riedl M, Thorner P, Licht C (2016) C3 Glomerulopathy and post-infectious glomerulonephritis define a disease spectrum. Pediatr Nephrol. doi:10.1007/s00467-015-3311-3
18. Noris M, Remuzzi G (2013) Overview of complement activation and regulation. Semin Nephrol 33:479–492
19. Riedl M, Fakhouri F, Lequintrec M, Noone D, Jungraithmayr TC, Fremeaux-Bacchi V, Licht C (2014) The spectrum of complement-mediated thrombotic microangiopathies—pathogenetic insights identifying novel treatment approaches. Semin Thromb Hemost 40:444–464
20. Noone D, Al-Matrafi J, Tinckam K, Zipfel PF, Herzenberg AM, Thorner PS, Pluthero FG, Kahr WHA, Filler G, Hebert D, Harvey E, Licht C (2012) Antibody mediated rejection associated with complement factor H-related protein 3/1 deficiency successfully treated with Eculizumab. Am J Transplant 12:2546–2553
21. Servais A, Noel L-H, Roumenina LT, Le Quintrec M, Ngo S, Dragon-Durey M-A, Macher M-A, Zuber J, Karras A, Provot F, Moulin B, Grunfeld J-P, Niaudet P, Lesavre P, Fremeaux-Bacchi V (2012) Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 82:454–464
22. Heinen S, Hartmann A, Lauer N, Wiehl U, Dahse HM, Schirmer S, Gropp K, Enghardt T, Wallich R, Halbich S, Mihlan M, Schlotzer-Schrehardt U, Zipfel PF, Skerka C (2009) Factor H-related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation. Blood 114:2439–2447
23. Goicoechea de Jorge E, Caesar JJ, Malik TH, Patel M, Colledge M, Johnson S, Hakobyan S, Morgan BP, Harris CL, Pickering MC, Lea SM (2013) Dimerization of complement factor H-related proteins modulates complement activation in vivo. Proc Natl Acad Sci USA 110:4685–4690
24. Xiao X, Pickering MC, Smith RJ (2014) C3 glomerulopathy: the genetic and clinical findings in dense deposit disease and c3 glomerulonephritis. Semin Thromb Hemost 40:465–471
25. Jansen JH, Hogasen K, Harboe M, Hovig T (1998) In situ complement activation in porcine membranoproliferative glomerulonephritis type II. Kidney Int 53:331–349
26. Pickering MC, Cook HT, Warren J, Bygrave AE, Moss J, Walport MJ, Botto M (2002) Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Nat Genet 31:424–428
27. Rose KL, Paixao-Cavalcante D, Fish J, Manderson AP, Malik TH, Bygrave AE, Lin T, Sacks SH, Walport MJ, Cook HT, Botto M, Pickering MC (2008) Factor I is required for the development of membranoproliferative glomerulonephritis in factor H-deficient mice. J Clin Invest 118:608–618
28. Pickering MC, Warren J, Rose KL, Carlucci F, Wang Y, Walport MJ, Cook HT, Botto M (2006) Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice. Proc Natl Acad Sci USA 103:9649–9654
29. de Jorge EG, Macor P, Paixao-Cavalcante D, Rose KL, Tedesco F, Cook HT, Botto M, Pickering MC (2011) The development of atypical hemolytic uremic syndrome depends on complement C5. J Am Soc Nephrol 22:137–145
30. Pickering MC, de Jorge EG, Martinez-Barricarte R, Recalde S, Garcia-Layana A, Rose KL, Moss J, Walport MJ, Cook HT, de Cordoba SR, Botto M (2007) Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J Exp Med 204:1249–1256
31. Paixao-Cavalcante D, Lopez-Trascasa M, Skattum L, Giclas PC, Goodship TH, de Cordoba SR, Truedsson L, Morgan BP, Harris CL (2012) Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation. Kidney Int 82:1084–1092
32. Licht C, Heinen S, Jozsi M, Loschmann I, Saunders RE, Perkins SJ, Waldherr R, Skerka C, Kirschfink M, Hoppe B, Zipfel PF (2006) Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II). Kidney Int 70:42–50
33. Martinez-Barricarte R, Heurich M, Valdes-Canedo F, Vazquez-Martul E, Torreira E, Montes T, Tortajada A, Pinto S, Lopez-Trascasa M, Morgan BP, Llorca O, Harris CL, De Cordoba SR (2010) Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. J Clin Invest 120:3702–3712
34. Vivarelli M, Emma F (2014) Treatment of C3 glomerulopathy with complement blockers. Semin Thromb Hemost 40:472–477
35. Spitzer RE, Stitzel AE (1988) On the origin and control of C3NeF. In Vivo 2:79–81
36. Schwertz R, Rother U, Anders D, Gretz N, Scharer K, Kirschfink M (2001) Complement analysis in children with idiopathic membranoproliferative glomerulonephritis: a long-term follow-up. Pediatr Allergy Immunol 12:166–172
37. Nicolas C, Vuiblet V, Baudouin V, Macher M-A, Vrillon I, Biebuyck-Gouge N, Dehennault M, Gie S, Morin D, Nivet H, Nobili F, Ulinski T, Ranchin B, Marinozzi MC, Ngo S, Fremeaux-Bacchi V, Pietrement C (2014) C3 nephritic factor associated with C3 glomerulopathy in children. Pediatr Nephrol 29:85–94
38. Fremeaux-Bacchi V, Weiss L, Brun P, Kazatchkine MD (1994) Selective disappearance of C3NeF IgG autoantibody in the plasma of a patient with membranoproliferative glomerulonephritis following renal transplantation. Nephrol Dial Transplant 9:811–814
39. Waldo FB, Forristal J, Beischel L, West CD (1985) A circulating inhibitor of fluid-phase amplification. C3 convertase formation in systemic lupus erythematosus. J Clin Invest 75:1786–1795
40. Wilson MR, Arroyave CM, Nakamura RM, Vaughan JH, Tan EM (1976) Activation of the alternative complement pathway in systemic lupus erythematosus. Clin Exp Immunol 26:11–20
41. Lewis LA, Ram S (2014) Meningococcal disease and the complement system. Virulence 5:98–126
42. Leroy V, Fremeaux-Bacchi V, Peuchmaur M, Baudouin V, Deschenes G, Macher M-A, Loirat C (2011) Membranoproliferative glomerulonephritis with C3NeF and genetic complement dysregulation. Pediatr Nephrol 26:419–424
43. Chen Q, Muller D, Rudolph B, Hartmann A, Kuwertz-Broking E, Wu K, Kirschfink M, Skerka C, Zipfel PF (2011) Combined C3b and factor B autoantibodies and MPGN type II. N Engl J Med 365:2340–2342
44. Strobel S, Zimmering M, Papp K, Prechl J, Jozsi M (2010) Anti-factor B autoantibody in dense deposit disease. Mol Immunol 47:1476–1483
45. Hofer J, Janecke AR, Zimmerhackl LB, Riedl M, Rosales A, Giner T, Cortina G, Haindl CJ, Petzelberger B, Pawlik M, Jeller V, Vester U, Gadner B, van Husen M, Moritz ML, Wurzner R, Jungraithmayr T (2013) Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 8:407–415
46. Jokiranta TS, Solomon A, Pangburn MK, Zipfel PF, Meri S (1999) Nephritogenic lambda light chain dimer: a unique human miniautoantibody against complement factor H. J Immunol 163:4590–4596
47. Sethi S, Sullivan A, Smith RJ (2014) C4 dense-deposit disease. N Engl J Med 370:784–786
48. Ohi H, Yasugi T (1994) Occurrence of C3 nephritic factor and C4 nephritic factor in membranoproliferative glomerulonephritis (MPGN). Clin Exp Immunol 95:316–321
49. Habbig S, Mihatsch MJ, Heinen S, Beck B, Emmel M, Skerka C, Kirschfink M, Hoppe B, Zipfel PF, Licht C (2009) C3 deposition glomerulopathy due to a functional factor H defect. Kidney Int 75:1230–1234
50. Levy M, Halbwachs-Mecarelli L, Gubler MC (1986) H deficiency in two brothers with atypical dense intramembranous deposit disease. Kidney Int 30:949–956
51. Ault BH, Schmidt BZ, Fowler NL, Kashtan CE, Ahmed AE, Vogt BA, Colten HR (1997) Human factor H deficiency. Mutations in framework cysteine residues and block in H protein secretion and intracellular catabolism. J Biol Chem 272:25168–25175
52. Dragon-Durey MA, Fremeaux-Bacchi V, Loirat C, Blouin J, Niaudet P, Deschenes G, Coppo P, Fridman WH, Weiss L (2004) Heterozygous and homozygous factor H deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases. J Am Soc Nephrol 15:787–795
53. Vogt BA, Wyatt RJ, Burke BA, Simonton SC, Kashtan CE (1995) Inherited factor H deficiency and collagen type III glomerulopathy. Pediatr Nephrol 9:11–15
54. Imamura H, Konomoto T, Tanaka E, Hisano S, Yoshida Y, Fujimura Y, Miyata T, Nunoi H (2015) Familial C3 glomerulonephritis associated with mutations in the gene for complement factor B. Nephrol Dial Transplant 30(5):862–864
55. Gale DP, de Jorge EG, Cook HT, Martinez-Barricarte R, Hadjisavvas A, McLean AG, Pusey CD, Pierides A, Kyriacou K, Athanasiou Y, Voskarides K, Deltas C, Palmer A, Fremeaux-Bacchi V, de Cordoba SR, Maxwell PH, Pickering MC (2010) Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet 376:794–801
56. Chen Q, Wiesener M, Eberhardt HU, Hartmann A, Uzonyi B, Kirschfink M, Amann K, Buettner M, Goodship T, Hugo C, Skerka C, Zipfel PF (2014) Complement factor H-related hybrid protein deregulates complement in dense deposit disease. J Clin Invest 124:145–155
57. Malik TH, Lavin PJ, De Jorge EG, Vernon KA, Rose KL, Patel MP, De Leeuw M, Neary JJ, Conlon PJ, Winn MP, Pickering MC (2012) A hybrid CFHR3-1 gene causes familial C3 glomerulopathy. J Am Soc Nephrol 23:1155–1160
58. Tortajada A, Yebenes H, Abarrategui-Garrido C, Anter J, Garcia-Fernandez JM, Martinez-Barricarte R, Alba-Dominguez M, Malik TH, Bedoya R, Cabrera Perez R, Lopez Trascasa M, Pickering MC, Harris CL, Sanchez-Corral P, Llorca O, Rodriguez de Cordoba S (2013) C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation. J Clin Invest 123:2434–2446
59. Abrera-Abeleda MA, Nishimura C, Smith JLH, Sethi S, McRae JL, Murphy BF, Silvestri G, Skerka C, Jozsi M, Zipfel PF, Hageman GS, Smith RJH (2006) Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease). J Med Genet 43:582–589
60. Hageman GS, Anderson DH, Johnson LV, Hancox LS, Taiber AJ, Hardisty LI, Hageman JL, Stockman HA, Borchardt JD, Gehrs KM, Smith RJ, Silvestri G, Russell SR, Klaver CC, Barbazetto I, Chang S, Yannuzzi LA, Barile GR, Merriam JC, Smith RT, Olsh AK, Bergeron J, Zernant J, Merriam JE, Gold B, Dean M, Allikmets R (2005) A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci USA 102:7227–7232
61. Abrera-Abeleda MA, Nishimura C, Frees K, Jones M, Maga T, Katz LM, Zhang Y, Smith RJH (2011) Allelic variants of complement genes associated with dense deposit disease. J Am Soc Nephrol 22:1551–1559
62. Dense Deposit Disease Focus Group, Smith RJH, Alexander J, Barlow PN, Botto M, Cassavant TL, Cook HT, de Cordoba SR, Hageman GS, Jokiranta TS, Kimberling WJ, Lambris JD, Lanning LD, Levidiotis V, Licht C, Lutz HU, Meri S, Pickering MC, Quigg RJ, Rops AL, Salant DJ, Sethi S, Thurman JM, Tully HF, Tully SP, van der Vlag J, Walker PD, Wurzner R, Zipfel PF (2007) New approaches to the treatment of dense deposit disease. J Am Soc Nephrol 18:2447–2456
63. Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaime F, Dragon-Durey MA, Ngo S, Moulin B, Servais A, Provot F, Rostaing L, Burtey S, Niaudet P, Deschenes G, Lebranchu Y, Zuber J, Loirat C (2013) Genetics and outcome of atypical hemolytic uremic syndrome: A nationwide French series comparing children and adults. Clin J Am Soc Nephrol 8:554–562
64. Coppo R, Gianoglio B, Porcellini MG, Maringhini S (1998) Frequency of renal diseases and clinical indications for renal biopsy in children (report of the Italian National Registry of Renal Biopsies in Children). Group of Renal Immunopathology of the Italian Society of Pediatric Nephrology and Group of Renal Immunopathology of the Italian Society of Nephrology. Nephrol Dial Transplant 13:293–297
65. Medjeral-Thomas NR, O'Shaughnessy MM, O'Regan JA, Traynor C, Flanagan M, Wong L, Teoh CW, Awan A, Waldron M, Cairns T, O'Kelly P, Dorman AM, Pickering MC, Conlon PJ, Cook HT (2014) C3 glomerulopathy: clinicopathologic features and predictors of outcome. Clin J Am Soc Nephrol 9:46–53
66. Lu D-F, Moon M, Lanning LD, McCarthy AM, Smith RJH (2012) Clinical features and outcomes of 98 children and adults with dense deposit disease. Pediatr Nephrol 27:773–781
67. Zhan X, Larson DE, Wang C, Koboldt DC, Sergeev YV, Fulton RS, Fulton LL, Fronick CC, Branham KE, Bragg-Gresham J, Jun G, Hu Y, Kang HM, Liu D, Othman M, Brooks M, Ratnapriya R, Boleda A, Grassmann F, Von Strachwitz C, Olson LM, Buitendijk GHS, Hofman A, Van Duijn CM, Cipriani V, Moore AT, Shahid H, Jiang Y, Conley YP, Morgan DJ, Kim IK, Johnson MP, Cantsilieris S, Richardson AJ, Guymer RH, Luo H, Ouyang H, Licht C, Pluthero FG, Zhang MM, Zhang K, Baird PN, Blangero J, Klein ML, Farrer LA, DeAngelis MM, Weeks DE, Gorin MB, Yates JRW, Klaver CCW, Pericak-Vance MA, Haines JL, Weber BHF, Wilson RK, Heckenlively JR, Chew EY, Stambolian D, Mardis ER, Swaroop A, Abecasis GR (2013) Identification of a rare coding variant in complement 3 associated with age-related macular degeneration. Nat Genet 45:1375–1381
68. Mullins RF, Russell SR, Anderson DH, Hageman GS (2000) Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. FASEB J 14:835–846
69. Mullins RF, Aptsiauri N, Hageman GS (2001) Structure and composition of drusen associated with glomerulonephritis: implications for the role of complement activation in drusen biogenesis. Eye 15:390–395
70. Mathieson PW, Wurzner R, Oliveria DB, Lachmann PJ, Peters DK (1993) Complement-mediated adipocyte lysis by nephritic factor sera. J Exp Med 177:1827–1831
71. Misra A, Peethambaram A, Garg A (2004) Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature. Medicine 83:18–34
72. Pickering MC, Cook HT (2008) Translational mini-review series on complement factor H: renal diseases associated with complement factor H: novel insights from humans and animals. Clin Exp Immunol 151:210–230
73. Brackman D, Sartz L, Leh S, Kristoffersson AC, Bjerre A, Tati R, Fremeaux-Bacchi V, Karpman D (2011) Thrombotic microangiopathy mimicking membranoproliferative glomerulonephritis. Nephrol Dial Transplant 26:3399–3403
74. Lorcy N, Rioux-Leclercq N, Lombard ML, Le Pogamp P, Vigneau C (2011) Three kidneys, two diseases, one antibody? Nephrol Dial Transplant 26:3811–3813
75. Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, Daina E, Fenili C, Castelletti F, Sorosina A, Piras R, Donadelli R, Maranta R, van der Meer I, Conway EM, Zipfel PF, Goodship TH, Remuzzi G (2010) Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 5:1844–1859
76. Cameron JS, Vick RM, Ogg CS, Seymour WM, Chantler C, Turner DR (1973) Plasma C3 and C4 concentrations in management of glomerulonephritis. Br Med J 3:668–672
77. Karumanchi SA, Thadhani R (2010) A complement to kidney disease: CFHR5 nephropathy. Lancet 376:748–750
78. Warady BA, Guggenheim SJ, Sedman A, Lum GM (1985) Prednisone therapy of membranoproliferative glomerulonephritis in children. J Pediatr 107:702–707
79. Braun MC, West CD, Strife CF (1999) Differences between membranoproliferative glomerulonephritis types I and III in long-term response to an alternate-day prednisone regimen. Am J Kidney Dis 34:1022–1032
80. Tarshish P, Bernstein J, Tobin JN, Edelmann CM Jr (1992) Treatment of mesangiocapillary glomerulonephritis with alternate-day prednisone—a report of the international study of kidney disease in children. Pediatr Nephrol 6:123–130
81. Yuan M, Zou J, Zhang X, Liu H, Teng J, Zhong Y, Ding X (2010) Combination therapy with mycophenolate mofetil and prednisone in steroid-resistant idiopathic membranoproliferative glomerulonephritis. Clin Nephrol 73:354–359
82. Dimkovic N, Jovanovic D, Kovacevic Z, Rabrenovic V, Nesic V, Savin M, Mitic B, Ratkovic M, Curic S, Mitic I, Pljesa S, Perunicic-Pekovic G, Marinkovic J, Popovic J, Vujic D (2009) Mycophenolate mofetil in high-risk patients with primary glomerulonephritis: Results of a 1-year prospective study. Nephron Clin Pract 111:c189–c196
83. Mazo A, Margieva T, Vashurina T, Zrobok O, Tsygin A (2013) The treatment of membranoproliferative glomerulonephritis in children with mycophenolate mofetil. Pediatr Nephrol 28:1607–1608
84. Bagheri N, Nemati E, Rahbar K, Nobakht A, Einollahi B, Taheri S (2008) Cyclosporine in the treatment of membranoproliferative glomerulonephritis. Arch Iran Med 11:26–29
85. Fan L, Liu Q, Liao Y, Li Z, Ji Y, Yang Z, Chen J, Fu J, Zhang J, Kong Y, Fu P, Lou T, Liu Z, Yu X, Chen W (2013) Tacrolimus is an alternative therapy option for the treatment of adult steroid-resistant nephrotic syndrome: a prospective, multicenter clinical trial. Int Urol Nephrol 45:459–468
86. Li X, Li H, Ye H, Li Q, He X, Zhang X, Chen Y, Han F, He Q, Wang H, Chen J (2009) Tacrolimus therapy in adults with steroid- and cyclophosphamide-resistant nephrotic syndrome and normal or mildly reduced GFR. Am J Kidney Dis 54:51–58
87. Haddad M, Lau K, Butani L (2007) Remission of membranoproliferative glomerulonephritis type I with the use of tacrolimus. Pediatr Nephrol 22:1787–1791
88. Appel GB, Cook HT, Hageman G, Jennette JC, Kashgarian M, Kirschfink M, Lambris JD, Lanning L, Lutz HU, Meri S, Rose NR, Salant DJ, Sethi S, Smith RJ, Smoyer W, Tully HF, Tully SP, Walker P, Welsh M, Wurzner R, Zipfel PF (2005) Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol 16:1392–1403
89. Dillon JJ, Hladunewich M, Haley WE, Reich HN, Cattran DC, Fervenza FC (2012) Rituximab therapy for Type I membranoproliferative glomerulonephritis. Clin Nephrol 77:290–295
90. Kong WY, Swaminathan R, Irish A (2013) Our experience with rituximab therapy for adult-onset primary glomerulonephritis and review of literature. Int Urol Nephrol 45:795–802
91. Perez-Saez MJ, Toledo K, Navarro MD, Lopez-Andreu M, Redondo MD, Ortega R, Perez-Seoane C, Aguera ML, Rodriguez-Benot A, Aljama P (2011) Recurrent membranoproliferative glomerulonephritis after second renal graft treated with plasmapheresis and rituximab. Transplant Proc 43:4005–4009
92. Sugiura H, Takei T, Itabashi M, Tsukada M, Moriyama T, Kojima C, Shiohira T, Shimizu A, Tsuruta Y, Amemiya N, Ogawa T, Uchida K, Tsuchiya K, Nitta K (2011) Effect of single-dose rituximab on primary glomerular diseases. Nephron Clin Pract 117:c98–c105
93. Guiard E, Karras A, Plaisier E, Duong Van Huyen J-P, Fakhouri F, Rougier J-P, Noel L-H, Callard P, Delahousse M, Ronco P (2011) Patterns of noncryoglobulinemic glomerulonephritis with monoclonal Ig deposits: correlation with IgG subclass and response to rituximab. Clin J Am Soc Nephrol 6:1609–1616
94. McCaughan JA, O'Rourke DM, Courtney AE (2012) Recurrent dense deposit disease after renal transplantation: an emerging role for complementary therapies. Am J Transplant 12:1046–1051
95. Daina E, Noris M, Remuzzi G (2012) Eculizumab in a patient with dense-deposit disease. N Engl J Med 366:1161–1163
96. Nord AT, Nord BL, Schmidt AE, Smith DS (2014) Management of dense deposit disease with plasmapheresis and eculizumab. J Clin Apher 29:28–29
97. McGinley E, Watkins R, McLay A, Boulton-Jones JM (1985) Plasma exchange in the treatment of mesangiocapillary glomerulonephritis. Nephron 40:385–390
98. Radhakrishnan S, Lunn A, Kirschfink M, Thorner P, Hebert D, Langlois V, Pluthero F, Licht C (2012) Eculizumab and refractory membranoproliferative glomerulonephritis. N Engl J Med 366:1165–1166
99. Oberkircher OR, Enama M, West JC, Campbell P, Moran J (1988) Regression of recurrent membranoproliferative glomerulonephritis type II in a transplanted kidney after plasmapheresis therapy. Transplant Proc 20:418–423
100. Kurtz KA, Schlueter AJ (2002) Management of membranoproliferative glomerulonephritis type II with plasmapheresis. J Clin Apher 17:135–137
101. Banks RA, May S, Wallington T (1982) Acute renal failure in dense deposit disease: recovery after plasmapheresis. Br Med J (Clin Res Ed) 284:1874–1875
102. Masutani K, Katafuchi R, Ikeda H, Yamamoto H, Motoyama K, Sugitani A, Kanai H, Kumagai H, Hirakata H, Tanaka M, Iida M (2005) Recurrent nephrotic syndrome after living-related renal transplantation resistant to plasma exchange: report of two cases. Clin Transplant 19[Suppl 14]:59–64
103. Montoliu J, Bergada E, Botey A, Torras A, Darnell A, Arrizabalaga P, Lopez-Pedret J, Revert L (1983) Plasmapheresis induced recovery from renal failure in mesangiocapillary glomerulonephritis of acute onset. Proc Eur Dial Transplant Assoc 19:794–799
104. Muczynski KA (1995) Plasmapheresis maintained renal function in an allograft with recurrent membranoproliferative glomerulonephritis type I. Am J Nephrol 15:446–449
105. Pipeleers L, Sennesael J, Massart A, Geers C, Goodship T, Stordeur P, Wissing KM (2012) Successful use of plasma exchange to prevent recurrence of C3 glomerulonephritis after kidney transplantation: a case report. Transplantation 94:1050
106. Saxena R, Frankel WL, Sedmak DD, Falkenhain ME, Cosio FG (2000) Recurrent type I membranoproliferative glomerulonephritis in a renal allograft: successful treatment with plasmapheresis. Am J Kidney Dis 35:749–752
107. Yadav P, Ognjanovic M, Coulthard M, Moghal N, Lambert H, Tse Y (2011) Recurrent (MPGN) membranoproliferative glomerulonephritis type 1 successfully treated with plasma exchange (PE). Pediatr Nephrol 26:1665–1666
108. Morton MR, Bannister KM (1993) Renal failure due to mesangiocapillary glomerulonephritis in pregnancy: use of plasma exchange therapy. Clin Nephrol 40:74–78
109. Roord JJ, van Diemen-van Steenvoorde RA, Schuurman HJ, Rijkers GT, Zegers BJ, Gmelig Meyling FH, Stoop JW (1989) Membranoproliferative glomerulonephritis in a patient with congenital deficiency of the third component of complement: effect of treatment with plasma. Am J Kidney Dis 13:413–417
110. Bomback AS, Smith RJ, Barile GR, Zhang Y, Heher EC, Herlitz L, Barry Stokes M, Markowitz GS, D'Agati VD, Canetta PA, Radhakrishnan J, Appel GB (2012) Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol 7:748–756
111. Daina E, Noris M, Remuzzi G (2012) Eculizumab in a patient with dense-deposit disease. N Engl J Med 366:1161–1163 [Erratum appears in N Engl J Med. 2012 366:1454]
112. Vivarelli M, Pasini A, Emma F (2012) Eculizumab for the treatment of dense-deposit disease. N Engl J Med 366:1163–1165
113. Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L (2007) Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 25:1256–1264
114. Gurkan S, Fyfe B, Weiss L, Xiao X, Zhang Y, Smith RJ (2013) Eculizumab and recurrent C3 glomerulonephritis. Pediatr Nephrol 28:1975–1981
115. Ozkaya O, Nalcacioglu H, Tekcan D, Genc G, Meydan BC, Ozdemir BH, Baysal MK, Keceligil HT (2014) Eculizumab therapy in a patient with dense-deposit disease associated with partial lipodystropy. Pediatr Nephrol 29:1283–1287
116. Rousset-Rouviere C, Cailliez M, Garaix F, Bruno D, Laurent D, Tsimaratos M (2014) Rituximab fails where eculizumab restores renal function in C3nef-related DDD. Pediatr Nephrol 29:1107–1111
117. Haffner K, Michelfelder S, Pohl M (2015) Successful therapy of C3Nef-positive C3 glomerulopathy with plasma therapy and immunosuppression. Pediatr Nephrol 30:1951–1959
118. Angelo JR, Bell CS, Braun MC (2011) Allograft failure in kidney transplant recipients with membranoproliferative glomerulonephritis. Am J Kidney Dis 57:291–299
119. Zand L, Lorenz EC, Cosio FG, Fervenza FC, Nasr SH, Gandhi MJ, Smith RJ, Sethi S (2014) Clinical findings, pathology, and outcomes of C3GN after kidney transplantation. J Am Soc Nephrol 25:1110–1117
120. Van Stralen KJ, Verrina E, Belingheri M, Dudley J, Dusek J, Grenda R, Macher MA, Puretic Z, Rubic J, Rudaitis S, Rudin C, Schaefer F, Jager KJ; ESPN/ERA-EDTA Registry (2013) Impact of graft loss among kidney diseases with a high risk of post-transplant recurrence in the paediatric population. Nephrol Dial Transplant 28:1031–1038